Osimertinib,Lenvatinib
Astrazeneca,Eisai
['biomarker']
dr. discusses neoadjuvant #egfr therapy at #asco23 css. in addition to dr. phase ii, other studies have been done and are ongoing. while these strategies evolve - important to identify these mutations with biomarker testing in the early stage setting. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo